ES2296665T3 - Proteina cinco-helice. - Google Patents
Proteina cinco-helice. Download PDFInfo
- Publication number
- ES2296665T3 ES2296665T3 ES00986475T ES00986475T ES2296665T3 ES 2296665 T3 ES2296665 T3 ES 2296665T3 ES 00986475 T ES00986475 T ES 00986475T ES 00986475 T ES00986475 T ES 00986475T ES 2296665 T3 ES2296665 T3 ES 2296665T3
- Authority
- ES
- Spain
- Prior art keywords
- helix
- hiv
- protein
- baselineskip
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 80
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 77
- 101800001690 Transmembrane protein gp41 Proteins 0.000 claims abstract description 66
- 230000004962 physiological condition Effects 0.000 claims abstract description 5
- 239000000470 constituent Substances 0.000 claims abstract 2
- 230000027455 binding Effects 0.000 claims description 29
- 230000004927 fusion Effects 0.000 claims description 29
- 239000013638 trimer Substances 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 27
- 239000003112 inhibitor Substances 0.000 claims description 21
- 241000700605 Viruses Species 0.000 claims description 19
- 108010005636 polypeptide C Proteins 0.000 claims description 18
- 208000031886 HIV Infections Diseases 0.000 claims description 17
- 230000015572 biosynthetic process Effects 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- 230000003612 virological effect Effects 0.000 claims description 15
- 208000037357 HIV infectious disease Diseases 0.000 claims description 14
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 14
- 230000002401 inhibitory effect Effects 0.000 claims description 13
- 208000015181 infectious disease Diseases 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 10
- 230000034217 membrane fusion Effects 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 8
- 101710091045 Envelope protein Proteins 0.000 claims description 7
- 101710188315 Protein X Proteins 0.000 claims description 7
- 210000004962 mammalian cell Anatomy 0.000 claims description 7
- 210000000170 cell membrane Anatomy 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 238000012360 testing method Methods 0.000 claims description 6
- 230000028993 immune response Effects 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 238000000423 cell based assay Methods 0.000 claims description 3
- 102100021696 Syncytin-1 Human genes 0.000 claims 4
- 108010075254 C-Peptide Proteins 0.000 description 64
- 108090000765 processed proteins & peptides Proteins 0.000 description 45
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 43
- 241000725303 Human immunodeficiency virus Species 0.000 description 39
- 210000004027 cell Anatomy 0.000 description 38
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 24
- 102000004196 processed proteins & peptides Human genes 0.000 description 21
- 230000005764 inhibitory process Effects 0.000 description 17
- 150000001413 amino acids Chemical class 0.000 description 16
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 15
- 238000013461 design Methods 0.000 description 14
- 239000012528 membrane Substances 0.000 description 14
- 125000000539 amino acid group Chemical group 0.000 description 13
- 210000004899 c-terminal region Anatomy 0.000 description 12
- 238000003556 assay Methods 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 229920000936 Agarose Polymers 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000007983 Tris buffer Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 239000000543 intermediate Substances 0.000 description 8
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 8
- 230000003472 neutralizing effect Effects 0.000 description 7
- 230000003389 potentiating effect Effects 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 239000004202 carbamide Substances 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 5
- 108060001084 Luciferase Proteins 0.000 description 5
- 239000005089 Luciferase Substances 0.000 description 5
- 210000004897 n-terminal region Anatomy 0.000 description 5
- 108010038279 peptide C34 Proteins 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 150000008575 L-amino acids Chemical class 0.000 description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- 239000002699 waste material Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 150000008574 D-amino acids Chemical class 0.000 description 3
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 230000036436 anti-hiv Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 108010005774 beta-Galactosidase Proteins 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000007910 cell fusion Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 230000003278 mimic effect Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- 102100026189 Beta-galactosidase Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 241001559185 Mammalian rubulavirus 5 Species 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000002983 circular dichroism Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000007499 fusion processing Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 210000003000 inclusion body Anatomy 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 108010062015 peptide N36 Proteins 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 239000000700 radioactive tracer Substances 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 230000017960 syncytium formation Effects 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 230000007502 viral entry Effects 0.000 description 2
- CFBILACNYSPRPM-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]amino]acetic acid Chemical compound OCC(N)(CO)CO.OCC(CO)(CO)NCC(O)=O CFBILACNYSPRPM-UHFFFAOYSA-N 0.000 description 1
- 229940124718 AIDS vaccine Drugs 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 101100450244 Dictyostelium discoideum hbx2 gene Proteins 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 241001635598 Enicostema Species 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 241000711950 Filoviridae Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 229940126154 HIV entry inhibitor Drugs 0.000 description 1
- 229940033330 HIV vaccine Drugs 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010027796 Membrane Fusion Proteins Proteins 0.000 description 1
- 102000018897 Membrane Fusion Proteins Human genes 0.000 description 1
- 206010027626 Milia Diseases 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 1
- 229940124411 anti-hiv antiviral agent Drugs 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000003508 chemical denaturation Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000002835 hiv fusion inhibitor Substances 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- -1 linkers amino acid Chemical class 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 101150079601 recA gene Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17104299P | 1999-12-16 | 1999-12-16 | |
| US171042P | 1999-12-16 | ||
| US23457200P | 2000-09-22 | 2000-09-22 | |
| US234572P | 2000-09-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2296665T3 true ES2296665T3 (es) | 2008-05-01 |
Family
ID=26866680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES00986475T Expired - Lifetime ES2296665T3 (es) | 1999-12-16 | 2000-12-15 | Proteina cinco-helice. |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US7053179B2 (enExample) |
| EP (1) | EP1237912B1 (enExample) |
| JP (1) | JP4925540B2 (enExample) |
| AT (1) | ATE380822T1 (enExample) |
| CA (1) | CA2395291C (enExample) |
| DE (1) | DE60037450T2 (enExample) |
| ES (1) | ES2296665T3 (enExample) |
| WO (1) | WO2001044286A2 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6841657B2 (en) | 1997-04-17 | 2005-01-11 | Whitehead Institute For Biomedical Research | Inhibitors of HIV membrane fusion |
| US6818740B1 (en) | 1997-04-17 | 2004-11-16 | Whitehead Institute For Biomedical Research | Inhibitors of HIV membrane fusion |
| US6150088A (en) | 1997-04-17 | 2000-11-21 | Whitehead Institute For Biomedical Research | Core structure of gp41 from the HIV envelope glycoprotein |
| US7960504B2 (en) | 1998-07-30 | 2011-06-14 | Whitehead Institute For Biomedical Research | Inhibitors of HIV membrane fusion |
| US6747126B1 (en) | 1998-07-30 | 2004-06-08 | Whitehead Institute For Biomedical Research | Peptide inhibitors of HIV entry |
| JP2003529319A (ja) * | 1999-01-08 | 2003-10-07 | キャロル ディ． ウエイス， | ＨＩＶ−１ｇｐ４１を標的化する広範に中和する抗体を誘発する方法 |
| DE60037450T2 (de) | 1999-12-16 | 2008-12-04 | Whitehead Institute For Biomedical Research, Cambridge | Fünf-helix protein |
| US20030082525A1 (en) * | 1999-12-16 | 2003-05-01 | Whitehead Institute For Biomedical Research | Five-Helix protein |
| FR2819256B1 (fr) * | 2001-01-05 | 2004-04-30 | Aventis Pasteur | Polypeptide induisant des anticorps neutralisant le vih |
| US6861253B2 (en) | 2001-01-05 | 2005-03-01 | Aventis Pasteur S.A. | Polypeptide inducing antibodies neutralizing HIV |
| ES2242860T3 (es) | 2001-05-31 | 2005-11-16 | Conjuchem, Inc. | Inhibidores peptidicos de fusion de larga vida contra infecciones por vih. |
| CN1255548C (zh) | 2001-06-15 | 2006-05-10 | 霍夫曼-拉罗奇有限公司 | gp41片段的乙酰化 |
| WO2003006056A2 (en) * | 2001-07-11 | 2003-01-23 | Genfa Zhou | End-locked five-helix protein |
| US20050208678A1 (en) * | 2001-09-27 | 2005-09-22 | Dong Xie | Anti-fusion assay |
| ES2275926T3 (es) | 2001-10-05 | 2007-06-16 | Sanofi Pasteur | Antigeno polipeptidico que forma una estructura que imita el estado intermedio de gp41. |
| US20030219451A1 (en) * | 2001-10-29 | 2003-11-27 | Whitehead Institute For Biomedical Research | Stable helical C peptides and uses therefor |
| FR2832715A1 (fr) * | 2001-11-29 | 2003-05-30 | Hippocampe | Polypeptides inhibiteurs de l'infectivite des virus de l'immunodeficience humaine |
| US20060241027A1 (en) * | 2002-02-07 | 2006-10-26 | Hans-Peter Hauser | Hiv inhibiting proteins |
| US7056519B2 (en) | 2002-05-17 | 2006-06-06 | Aventis Pasteur S.A. | Methods for inducing HIV-neutralizing antibodies |
| US20040076637A1 (en) * | 2002-09-27 | 2004-04-22 | Delmedico Mary Kay | HIV-derived HR1 peptides modified to form stable trimers, and their use in therapy to inhibit transmission of human immunodeficiency virus |
| CA2443365C (en) * | 2002-11-19 | 2010-01-12 | F. Hoffmann-La Roche Ag | Methods for the recombinant production of antifusogenic peptides |
| WO2005018666A1 (en) * | 2003-08-14 | 2005-03-03 | The Government Of The United States Of America, As Represented By The Department Of Health And Human Services | Polypeptide multimers having antiviral activity |
| CA2565658A1 (en) * | 2004-05-06 | 2005-11-17 | Conjuchem Biotechnologies Inc. | Compounds for specific viral target |
| EP1755667B1 (en) | 2004-06-01 | 2013-07-17 | Merck Sharp & Dohme Corp. | Stable peptide mimetic of hiv gp41 fusion intermediate |
| WO2005118887A2 (en) | 2004-06-01 | 2005-12-15 | Merck & Co., Inc. | Human antibodies interacting with hiv gp41 |
| US7491489B2 (en) * | 2004-11-22 | 2009-02-17 | The University Of Hong Knog | Synthetic peptide targeting critical sites on the SARS-associated coronavirus spike protein responsible for viral infection and method of use thereof |
| EP1868652A2 (en) * | 2005-04-05 | 2007-12-26 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Method for shielding functional sites or epitopes on proteins |
| CN101088557A (zh) | 2006-06-12 | 2007-12-19 | 天津市扶素生物技术有限公司 | 用于预防或治疗hiv感染的药用组合物及其应用 |
| JP2010521478A (ja) * | 2007-03-12 | 2010-06-24 | トーマス・ジェファーソン・ユニバーシティ | Ｈｉｖ−１侵入に対する強固に結合したｃ−ペプチド阻害剤 |
| US9217011B2 (en) * | 2007-09-07 | 2015-12-22 | Complix Nv | Non-natural proteinaceous scaffold made of three non-covalently associated peptides |
| GB0720503D0 (en) * | 2007-10-22 | 2007-11-28 | Angeletti P Ist Richerche Bio | New compound |
| GB2471692A (en) * | 2009-07-08 | 2011-01-12 | Complix Nv | HIV gp41-binding single-chain coiled-coil peptide comprising heptad repeats |
| US9050063B2 (en) * | 2012-03-30 | 2015-06-09 | Sandance Technology Llc | Systems and methods for determining suitability of a mechanical implant for a medical procedure |
| CN106946994B (zh) * | 2017-03-09 | 2019-11-26 | 中国医学科学院病原生物学研究所 | 一种抑制丙型肝炎病毒感染的蛋白及其应用 |
| CN110551179B (zh) * | 2018-05-31 | 2022-03-15 | 中国科学院微生物研究所 | 一种经修饰的抗hiv多肽及其制备方法和用途 |
| WO2023213758A1 (en) | 2022-05-03 | 2023-11-09 | F. Hoffmann-La Roche Ag | Hiv gp41 variants for immunodiagnostic assays |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5444044A (en) | 1992-03-26 | 1995-08-22 | New York Blood Center | Synthetic polypeptides as inhibitors of HIV-1 |
| KR100358209B1 (ko) | 1992-07-20 | 2003-01-24 | 듀크 유니버시티 | Hiv복제를저해하는조성물 |
| US5464933A (en) | 1993-06-07 | 1995-11-07 | Duke University | Synthetic peptide inhibitors of HIV transmission |
| US5780221A (en) * | 1995-05-03 | 1998-07-14 | Whitehead Institute For Biomedical Research | Identification of enantiomeric ligands |
| CN1192688A (zh) | 1995-06-07 | 1998-09-09 | 特莱默里斯公司 | 联合疗法治疗hiv和其它病毒性感染 |
| JP3903503B2 (ja) | 1996-11-18 | 2007-04-11 | 住友電気工業株式会社 | 可溶性ポリペプチド |
| US6303317B1 (en) | 1997-01-28 | 2001-10-16 | The Regents Of The University Of California | Peptide probes and methods for making the same |
| US6150088A (en) * | 1997-04-17 | 2000-11-21 | Whitehead Institute For Biomedical Research | Core structure of gp41 from the HIV envelope glycoprotein |
| US6818740B1 (en) * | 1997-04-17 | 2004-11-16 | Whitehead Institute For Biomedical Research | Inhibitors of HIV membrane fusion |
| US6841657B2 (en) | 1997-04-17 | 2005-01-11 | Whitehead Institute For Biomedical Research | Inhibitors of HIV membrane fusion |
| US6090911A (en) | 1997-10-22 | 2000-07-18 | University Of Massachusetts | Reversible hydrogels |
| US6656906B1 (en) * | 1998-05-20 | 2003-12-02 | Trimeris, Inc. | Hybrid polypeptides with enhanced pharmacokinetic properties |
| US7960504B2 (en) * | 1998-07-30 | 2011-06-14 | Whitehead Institute For Biomedical Research | Inhibitors of HIV membrane fusion |
| KR20010099605A (ko) | 1998-07-30 | 2001-11-09 | 존 프랫 | Ｈｉｖ 막융합 억제제 |
| US6747126B1 (en) * | 1998-07-30 | 2004-06-08 | Whitehead Institute For Biomedical Research | Peptide inhibitors of HIV entry |
| WO2002024735A2 (en) | 2000-09-22 | 2002-03-28 | Whitehead Institute For Biomedical Research | Peptide inhibitors of hiv entry |
| JP2003529319A (ja) * | 1999-01-08 | 2003-10-07 | キャロル ディ． ウエイス， | ＨＩＶ−１ｇｐ４１を標的化する広範に中和する抗体を誘発する方法 |
| US20030082525A1 (en) | 1999-12-16 | 2003-05-01 | Whitehead Institute For Biomedical Research | Five-Helix protein |
| DE60037450T2 (de) | 1999-12-16 | 2008-12-04 | Whitehead Institute For Biomedical Research, Cambridge | Fünf-helix protein |
-
2000
- 2000-12-15 DE DE60037450T patent/DE60037450T2/de not_active Expired - Lifetime
- 2000-12-15 WO PCT/US2000/034194 patent/WO2001044286A2/en not_active Ceased
- 2000-12-15 AT AT00986475T patent/ATE380822T1/de not_active IP Right Cessation
- 2000-12-15 EP EP00986475A patent/EP1237912B1/en not_active Expired - Lifetime
- 2000-12-15 CA CA2395291A patent/CA2395291C/en not_active Expired - Fee Related
- 2000-12-15 JP JP2001544774A patent/JP4925540B2/ja not_active Expired - Fee Related
- 2000-12-15 ES ES00986475T patent/ES2296665T3/es not_active Expired - Lifetime
- 2000-12-15 US US09/738,945 patent/US7053179B2/en not_active Expired - Fee Related
-
2005
- 2005-06-13 US US11/151,598 patent/US7504224B2/en not_active Expired - Fee Related
-
2009
- 2009-01-20 US US12/321,300 patent/US8058012B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20010047080A1 (en) | 2001-11-29 |
| US8058012B2 (en) | 2011-11-15 |
| JP2003517006A (ja) | 2003-05-20 |
| WO2001044286A2 (en) | 2001-06-21 |
| WO2001044286A3 (en) | 2002-01-24 |
| EP1237912B1 (en) | 2007-12-12 |
| DE60037450T2 (de) | 2008-12-04 |
| ATE380822T1 (de) | 2007-12-15 |
| DE60037450D1 (de) | 2008-01-24 |
| CA2395291A1 (en) | 2001-06-21 |
| CA2395291C (en) | 2012-09-11 |
| US20100196397A1 (en) | 2010-08-05 |
| EP1237912A2 (en) | 2002-09-11 |
| JP4925540B2 (ja) | 2012-04-25 |
| US7053179B2 (en) | 2006-05-30 |
| US7504224B2 (en) | 2009-03-17 |
| US20060014139A1 (en) | 2006-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8058012B2 (en) | Five-helix protein | |
| US7811578B2 (en) | Soluble chimeric peptide inhibitors of HIV entry comprising an IZ trimeric coiled-coil peptide and HIV gp41 N-helix coiled-coil peptide | |
| JP5788178B2 (ja) | ウィルス感染症の治療のための組成物及び方法 | |
| Root et al. | Protein design of an HIV-1 entry inhibitor | |
| ES2238674T3 (es) | Inhibidores peptidicos sinteticos de la transmision de hiv. | |
| EP0652895B1 (en) | Compounds which inhibit hiv replication | |
| US8372407B2 (en) | Chimeric HIV fusion proteins as vaccines | |
| PL363071A1 (pl) | Sposoby i kompozycje dla zmniejszenia replikacji HIV-1 | |
| US20030082525A1 (en) | Five-Helix protein | |
| AU2005225063B2 (en) | Peptide inhibitors of HIV entry | |
| US8828931B2 (en) | Bifunctional molecules for inhibiting HIV entry | |
| TW201343670A (zh) | Ｈｉｖ－１ ｇｐ４１類髮夾中間體之安定肽模擬物 | |
| AU2001292944A1 (en) | Peptide inhibitors of HIV entry | |
| Pan et al. | A novel chimeric protein-based HIV-1 fusion inhibitor targeting gp41 glycoprotein with high potency and stability | |
| ES2260416T3 (es) | Polipeptido que induce anticuerpos que neutralizan el vih. | |
| ES2202321T3 (es) | Peptidos para uso en la vacunacion de anticuerpos neutralizantes contra el virus de la inmunodeficiencia humana. | |
| US20030219451A1 (en) | Stable helical C peptides and uses therefor | |
| Wang et al. | Design of artificial α-helical peptides targeting both gp41 deep pocket and subpocket as potent HIV-1 fusion inhibitors | |
| Sia | Rational design of peptide inhibitors of HIV-1 entry |